Can a biotech uni­corn break in­to the record books with a $600M IPO? Stéphane Ban­cel has a for­tune rid­ing on the an­swer

Stéphane Ban­cel’s life is about to change dra­mat­i­cal­ly.

The Mod­er­na CEO and his crew have post­ed the de­tails on their shot at the biggest biotech IPO in the in­dus­try’s his­to­ry. And Ban­cel will have a per­son­al for­tune of more than $700 mil­lion rid­ing on the out­come — if they can score a record suc­cess.

In a new fil­ing Mod­er­na $MR­NA got around to out­lin­ing who con­trols the stock at the mes­sen­ger RNA com­pa­ny, which has a val­u­a­tion scrap­ing $7.8 bil­lion un­der a bull­ish sce­nario. Flag­ship — rep­re­sent­ed by Noubar Afeyan, who seed­ed the com­pa­ny at the ven­ture group — weighs in at the top rank with 18% of the shares.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.